Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.56 |
| ▸ | CA1 | P00915 | 15/20 | 0.56 |
| ▸ | MMP1 | P03956 | 6/20 | 0.56 |
| ▸ | MMP2 | P08253 | 6/20 | 0.56 |
| ▸ | MMP9 | P14780 | 6/20 | 0.56 |
| ▸ | MMP8 | P22894 | 6/20 | 0.56 |
| ▸ | MMP13 | P45452 | 6/20 | 0.56 |
| ▸ | F2 | P00734 | 4/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28375339 | 0.98 | CA2 (0.57) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL7884221 | 0.98 | CA2 (0.57) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL1851655 | 0.98 | CA2 (0.57) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL7884226 | 0.98 | CA2 (0.57) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL19042198 | 0.94 | CA2 (0.49) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL19042201 | 0.89 | CA2 (0.53) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL6260406 | 0.87 | CA2 (0.53) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL7881220 | 0.87 | CA2 (0.51) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL9347611 | 0.85 | EPHX1 (0.39) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL7884131 | 0.84 | CA2 (0.50) | CA2CA1MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117757488-A | Preparation method and application of nonionic fluorine-containing surfactant | 福建泓光半导体材料有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-116607152-B | High-temperature-resistant corrosion inhibitor and synthesis method thereof | 东营市宝泽能源科技有限公司 | 2023-09-15 | — | — | CN | claimed |
| CN-116607152-A | High-temperature-resistant corrosion inhibitor and synthesis method thereof | 东营市宝泽能源科技有限公司 | 2023-08-18 | — | — | CN | claimed |
| CN-113308233-B | High-temperature-resistant high-pressure-resistant high-sulfur-content corrosion inhibitor | 西南石油大学 | 2022-05-13 | — | — | CN | claimed |
| CN-113308233-A | High-temperature-resistant high-pressure-resistant high-sulfur-content corrosion inhibitor | 西南石油大学 | 2021-08-27 | — | — | CN | claimed |
| WO-2010074877-A1 | METHOD OF MAKING A COMPOSITION AND AQUEOUS COMPOSITION PREPARABLE THEREBY | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-07-01 | — | — | WO | claimed |
| CN-122036565-A | Preparation method of 1,2, 3, 4-nonafluorobutane-1-sulfonic acid (2-hydroxyethyl) -amide | 福建邦孚新材料有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12599949-B2 | Devices and methods for performing shear-assisted extrusion and extrusion processes | BATTELLE MEMORIAL INSTITUTE (US) | 2026-04-14 | — | — | US | disclosed |
| US-12583764-B2 | PFAS treatment process for liquid effluent | SUEZ INTERNATIONAL (FR) | 2026-03-24 | — | — | US | disclosed |
| EP-4034316-B1 | SHAPE PROCESSES | BATTELLE MEMORIAL INSTITUTE (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12551946-B2 | Devices and methods for performing shear-assisted extrusion and extrusion processes | BATTELLE MEMORIAL INSTITUTE (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4680778-A1 | EXTRUSION FEEDSTOCK AND PRODUCT THEREOF INCLUDING EXTRUDABLE ALUMINUM SCRAP | Battelle Memorial Institute (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4185555-B1 | PFAS TREATMENT PROCESS FOR LIQUID EFFLUENT | SUEZ INT (FR) | 2025-10-01 | — | — | EP | disclosed |
| CN-104937004-A | POLYURETHANE POLYMER, SYNTHETIC LEATHER, AND METHOD | 3M INNOVATIVE PROPERTIES CO | 2015-09-23 | — | — | CN | disclosed |
| EP-2449000-A1 | COMPOSITION AND PROCESS FOR PREPARING CURABLE ORGANOFLUORINE-MODIFIED POLYSILAZANES, AND POLYSILAZANES PREPARED THEREBY | 3M Innovative Properties Company (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011002666-A1 | COMPOSITION AND PROCESS FOR PREPARING CURABLE ORGANOFLUORINE-MODIFIED POLYSILAZANES, AND POLYSILAZANES PREPARED THEREBY | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20100155657-A1 | AQUEOUS COMPOSITION CONTAINING FLUORINATED SULFONAMIDE AND SULFONAMIDATE COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20100160458-A1 | METHOD OF MAKING A COMPOSITION AND AQUEOUS COMPOSITION PREPARABLE THEREBY | 3M INNOVATIVE PROPERTIES COMPANY | 2010-06-24 | — | — | US | disclosed |
| EP-1670839-A1 | STAIN RESISTANT POLYURETHANE COATINGS | 3M Innovative Properties Company (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005037884-A1 | STAIN RESISTANT POLYURETHANE COATINGS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551946-B2 | Devices and methods for performing shear-assisted extrusion and extrusion processes | EIF4E, STIP1, PIEZO1 | CA2 4574/4885CA1 4656/4885MMP1 1290/4885 |
| US-12583764-B2 | PFAS treatment process for liquid effluent | PFAS, FGB, FGR | CA2 1644/4885CA1 1497/4885MMP1 3259/4885 |
| US-12599949-B2 | Devices and methods for performing shear-assisted extrusion and extrusion processes | DVL1, DVL3, FZD7 | CA2 3597/4885CA1 3391/4885MMP1 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.